Quick note to readers: This was Audrey’s last week (in review) at P4AD! She’s been honored to be in your inbox for the last couple years. We’ll be excited to announce P4AD’s incoming communications and media director very soon and we’ll see you here next week as usual. 

Welcome to the Week in Review.

1. Enrolling In Medicare? The Inflation Reduction Act Will Bring Savings

 2.  Patients Depend On Patent & Regulatory Reforms

3. Addressing Launch Prices Of Gene Therapies

PRICE GOUGING ALERT: This week we learned Pfizer plans to set the U.S. price for its COVID-19 antiviral treatment Paxlovid at nearly $1,400. That’s more than double what the government currently pays and far more than what it costs to make. Outrageous. 

Have a great weekend!